In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Aridis Pharmaceuticals Inc (ARDS), with a price target of $25. The company’s shares opened today at $11.84.
McCarthy commented:
“On 3/28, Aridis reported YE18 results with $2.8M in revenue (grants) and a net loss of ($23.5M). The company ended the year with $24M in cash on the balance sheet.”
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -7.3% and a 30.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.
Currently, the analyst consensus on Aridis Pharmaceuticals Inc is a Moderate Buy with an average price target of $32.50, implying a 174.5% upside from current levels. In a report issued on March 28, Cantor Fitzgerald also maintained a Buy rating on the stock with a $25 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.85 and a one-year low of $7.59. Currently, Aridis Pharmaceuticals Inc has an average volume of 4,259.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.
